Boston Scientific maintained at sector perform by RBC

RBC Capital Markets analyst Phil Nalbone maintained Boston Scientific Corp. at sector perform, above average risk, with a price target of $24. The company reported second-quarter sales of $2.11 billion, in line with the analyst's low-end forecast. Important to the quarter were strengthening Taxus drug-eluting stent sales declining Cardiac Rhythm Management trends in the recently acquired Guidant business, according to the analyst. Worldwide Taxus sales of $647 million represented about 31% of the company's total revenues for the quarter. Shares of the Natick, Mass.-based pharmaceutical company were down 25 cents, or 1.41%, at $17.50 on volume of 7,626,600 shares versus the three-month running average of 12,735,900 shares. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.